Meghan Karuturi
Department of Breast Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2016 | University of Texas Graduate School of Biomedical Science, Houston, Texas, US, Clinical Research, M.Sc |
| 2008 | George Washington University, Washington, DC, US, MD |
| 2004 | George Washington University, Washington, DC, US, Biology, BA |
Postgraduate Training
| 2011-2014 | Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2009-2011 | Clinical Residency, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania |
| 2008-2009 | Clinical Internship, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania |
Licenses & Certifications
| 2014 | Medical Oncology |
| 2012 | Texas Medical Board |
| 2011 | Internal Medicine |
Experience & Service
Faculty Academic Appointments
Associate Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2026
Assistant Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2020
Clinical Fellowship, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2014
Clinical Residency, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 2009 - 2011
Clinical Internship Training, Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 2008 - 2009
Other Professional Positions
Member, Alliance Scientific Concept Review Committee (SCRC), Alliance for Clinical Trials Oncology, Chicago, IL, 2019 - Present
Member, R21/33 CARING Infrastructure Grant (CARinG) Junior Investigator Board, CARING, Rockville, MD, 2019 - Present
Member, Alliance Cancer in the Elderly Committee, Alliance for Clinical Trials Oncology, Chicago, IL, 2018 - Present
Member, Advisory Committee of Association of Cancer Center's Geriatric Oncology, Association of Community Cancer Center, Rockville, MD, 2018 - Present
Member, Cancer and Aging Research Group, Los Angeles, CA, 2014 - Present
Extramural Institutional Committee Activities
Member, Advisory Committee of Association of Community Cancer Center's Geriatric Oncology, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, Clinical Effectiveness Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Lead, Older Adult Working Group, Nelle B. Connally Breast Center, The University of Texas MD Anderson Cancer Center, 2017 - Present
Consultant, MD Anderson Physician Network, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Geriatric Oncology Breast Cancer Working Group, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Cancer and Aging Research Group, The University of Texas MD Anderson Cancer Center, 2017 - Present
Chair, Hormone-Receptor Positive Clinical Trial Working Group, The University of Texas MD Anderson Cancer Center, 2014 - Present
Honors & Awards
| 2018 | Breast Surgical Fellowship Multidisciplinary Teaching Award |
| 2018 | Butler-Williams Scholars Program, National Institute on Aging (NIA), National Instiitute of Health (NIH) |
| 2014 | ASCO Young Investigator Award |
| 2014 | Lyndon B. Johnson 3rd Year Fellow of the Year Award |
| 2013 | NCCN Fellows Recognition Awardee |
| 2007 | AOA Student Service Project Award |
| 2003 | Pembroke College, Oxford Fellowship Recipient: Junior Year Abroad Program |
| 2002 | Shapiro Award for Public Service |
| 2001 | Seven-Year Accelerated Combined BA/MD Program with Scholarship |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2021. Updates on Geriatrics. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2020. Optimizing the paradigm shift by CDK4/6 inhibition in metastatic HR-positive, HER2-negative breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2020. Breast cancer management in the elderly. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2020. Geriatric care in older adults with metastatic breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2019. Endocrine and other treatments beyond second line therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2019. Breast cancer in older patients. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2018. Treatment of cancer in older adults. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Managing special populations: Pregnant, elderly. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Treatment of cancer in older adults. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. San Antonio Breast Cancer Symposium update on ER+ trials of interest. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Issues in treating early HER-2 positive disease. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
National Presentations
- 2012. Overall survival benefit for patients with relapse Hodgkin lymphoma treated with brentuximab vedotin after autologous stem cell transplant. Conference. Annual ASH Meeting. San Francisco, CA, US.
- 2010. Plasmacytic post-transplant lymphoproliferative disorder. Invited. 10th American Transplant Congress. San Diego, CA, US.
International Presentations
- 2019. Poster presented: Measures of functional status in adults aged> 70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS. Invited. ESMO Congress. Barcelona, ES.
- 2019. Presented poster: Exploring and supporting older women's chemotherapy decision-making in early stage breast cancer. Invited. ASCO Quality Care Symposium. San Diego, US.
- 2018. Presented poster: Decision making needs of older adult women considering chemotherapy for early stage breast cancer: A needs assessment of older adult women with breast cancer. Invited. 18th Annual SIOG Conference. Amsterdam, NL.
- 2018. Presented poster: The impact of dose delays and reductions on progression free survival in older patients with metastatic breast cancer receiving palbocilib. Invited. 11th European Breast Cancer Conference (EBCC). Barcelona, ES.
- 2017. Use of Stopp criteria medications in older breast and colorectal patients. Invited. MASCC Annual Meeting. Washington, US.
- 2016. Presented poster: Potentially inappropriate medication use in elderly breast and colorectal cancer patients. Invited. Annual SIOG Conference. Geneva, CH.
- 2015. Potentially inappropriate medication use in elderly breast cancer patients. Invited. Annual ASCO Meeting. Chicago, US.
- 2013. Improving the care of acute lymphocytic leukemia (ALL) at a large county hospital. Conference. ASCO's Quality Care Symposium. San Diego, US.
Grant & Contract Support
| Date: | 2022 - 2023 |
| Title: | Treatment Non-Completion Among Patients with Breast Cancer: Impact and Associated Factors |
| Funding Source: | BCRF |
| Role: | Investigator |
| Date: | 2020 - 2022 |
| Title: | The EXCitE Study: Exercise during chemotherapy in older women with early-stage breast cancer |
| Funding Source: | IRG |
| Role: | PI |
| ID: | 2019-0638 |
| Date: | 2020 - 2022 |
| Title: | Implementation of a geriatric care survivorship intervention in older adults who have completed curative intent therapy for early stage breast cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center (Survivorship IRG Grant Award) |
| Role: | PI |
| ID: | 01 |
| Date: | 2020 - 2022 |
| Title: | Implementation of a Geriatric Care Survivorship Intervention in Older Adults who have Completed Curative Intent Therapy for Early-Stage Breast Cancer |
| Funding Source: | Survivorship IRG |
| Role: | PI |
| Date: | 2019 - 2024 |
| Title: | Developing a decision tool for chemotherapy in older women with early stage breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | CA241087 |
| Date: | 2019 - 2022 |
| Title: | Phase Ib study of BYL719 (Alpelisib) in combination with androgen receptor inhibitor (Enzalutamide) in Patients with Androgen Receptor (AR) positive PTEN positive metastatic breast cancer |
| Funding Source: | Novartis |
| Role: | PI |
| ID: | 2016-0538 |
| Date: | 2018 - 2025 |
| Title: | TBRCR 41 Randomized Phase II trial to evaluate Alisertib alone or combined with Fulvestrant in women with advanced, hormone-receptor positive breast cancer |
| Funding Source: | Mayo Clinic |
| Role: | PI |
| ID: | 2018-0540 |
| Date: | 2018 - 2025 |
| Title: | TBCRC 41 Randomized Phase II Trial to Evaluate Alisertib Alone or Combined with Fulvestrant in Women with Advanced, Hormone-Receptor Positive (HR+) Breast Cancer |
| Funding Source: | Mayo Clinic |
| Role: | PI |
| ID: | 2018-0540 |
| Date: | 2018 - 2022 |
| Title: | Core 1: Rational combination treatment options to reverse resistance in hormone receptor positive breast cancer refractory to standard therapy |
| Funding Source: | CPRIT |
| Role: | Investigator |
| ID: | RP180712 |
| Date: | 2018 - 2022 |
| Title: | Rational combination treatment options to reverse resistance in hormone receptor positive breast cancer refractory to standard therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP180712 |
| Date: | 2018 - 2021 |
| Title: | EMD Serono Strategic Collaboration Agreement |
| Funding Source: | EMD Serono, Inc |
| Role: | PI |
| ID: | CS2017-00053902-LG |
| Date: | 2018 - 2019 |
| Title: | SIV EMD Serono Strategic Collaboration Agreement |
| Funding Source: | EMD Serono Inc |
| Role: | PI |
| ID: | CS2017-00053902-LG |
| Date: | 2017 - 2023 |
| Title: | Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced-recurrent breast cancer (MBC) |
| Funding Source: | Pfizer |
| Role: | Collaborator |
| ID: | 2016-0419 |
| Date: | 2017 - 2024 |
| Title: | POLARIS palbociclib in hormone receptor positive advanced breast cancer: A prospective multicenter non-interventional study |
| Funding Source: | Pfizer Pharmaceuticals |
| Role: | PI |
| ID: | PA17-0217 |
| Date: | 2016 - 2023 |
| Title: | Phase 1b Study to Assess the Safety, Tolerability , and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC) |
| Funding Source: | Pfizer |
| Role: | Investigator |
| ID: | 2016-0419 |
| Date: | 2016 - 2019 |
| Title: | Developing a decision aid for adjuvant chemotherapy in elderly women with early stage breast cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center (IRG Grant Award) |
| Role: | PI |
| ID: | 2016-0055 |
| Date: | 2016 - 2023 |
| Title: | A Phase I/II, Single Arm, Open-Label Study of Ribociclib in Combination with Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women with HR+, HER2- Locally Advanced or Metastatic Breast Cancer |
| Funding Source: | Novartis |
| Role: | PI |
| ID: | 2016-0418 |
| Date: | 2016 - 2023 |
| Title: | TRINITY-I: A phase I/II, single arm, open-label study of ribociclib in combination with everolimus+ exemestance in the treatment of men and postmenopausal women with HR+, HER2-locally advanced breast cancer |
| Funding Source: | Novartis |
| Role: | PI |
| ID: | 2016-0418 |
| Date: | 2016 - 2020 |
| Title: | A phase I/Ib, open label study of LSZ102 single agent and LSZ102 in combination with either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in patients with advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy |
| Funding Source: | Novartis |
| Role: | Investigator |
| ID: | 2016-0260 |
| Date: | 2015 - 2016 |
| Title: | Impact of physical activity on Biomarker of aging and body composition among Breast Cnacer Survivors Age 65 and Older |
| Funding Source: | University of North Carolina at Chapel Hill |
| Role: | PI |
| ID: | 2015-0276 |
| Date: | 2015 - 2018 |
| Title: | A Multicenter, Open-Label, Phase 1, Two-Part Dose Escalation Study of RAD1901 in Post-Menopausal Women with Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer |
| Funding Source: | Radius Health Inc |
| Role: | PI |
| ID: | 2015-0183 |
| Date: | 2015 - 2021 |
| Title: | MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment |
| Funding Source: | Novartis |
| Role: | PI |
| ID: | 2015-0321 |
| Date: | 2014 - 2015 |
| Title: | Polypharmacy in elderly adults received adjuvant therapy for breast and colorectal cancer |
| Funding Source: | ASCO Conquer Cancer |
| Role: | PI |
| ID: | 14017482 |
Selected Publications
Peer-Reviewed Articles
- Tripathy, D, Blum, JL, Karuturi, MS, McCune, S, Kurian, S, Moezi, M, Anderson, D, Ji, Y, Pluard, T, Migas, J, Lakhanpal, S, Jepsen, E, Wang, Y, Montelongo, MZ, Zhang, Z, Cappelleri, JC, Gauthier, E, Rocque, GB. Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2−) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study. Cancer medicine 15(4), 2026. e-Pub 2026. PMID: 42017805.
- Rocque G, Blum JL, Ji Y, Pluard T, Migas J, Lakhanpal S, Jepsen E, Gauthier E, Wang Y, Montelongo MZ, Cappelleri JC, Chen C, Karuturi MS, Tripathy D. Enhancing the interpretation of real-world quality of life in patients with HR+/HER2- advanced breast cancer enrolled in the POLARIS study. Oncologist, 2025. e-Pub 2025. PMID: 40971858.
- Tripathy D, Blum JL, Zhang H, Deng S, McCune SL, Patel K, Wang Y, Lakhanpal S, Karuturi MS, Zhang Z, Deshpande C, Montelongo MZ, Gauthier E, Liu Y, Rocque GB, Bardia A. Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study. JCO Precis Oncol 9:e2400810, 2025. e-Pub 2025. PMID: 40825169.
- Sullivan M, Lei X, Karuturi M, Malinowski C, Giordano SH, Chavez-MacGregor M. Use of adjuvant capecitabine in older patients with early-stage triple-negative breast cancer. Breast Cancer Res Treat 211(1):213-221, 2025. e-Pub 2025. PMID: 40019667.
- Rocque GB, Blum JL, Ji Y, Pluard T, Migas J, Lakhanpal S, Jepsen E, Gauthier E, Wang Y, Montelongo MZ, Cappelleri JC, Karuturi MS, Tripathy D. Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Res Treat 209(3):613-627, 2025. e-Pub 2025. PMID: 39581892.
- Muppidi N, Adesoye T, Yi M, Sun SX, Chavez-MacGregor M, Singh P, Karuturi M, Tamirisa N, Hunt KK, Teshome M. ASO Visual Abstract: Clinical Outcomes for Early-Stage Node-Negative HER2-Positive Breast Cancer Patients Receiving Upfront Surgery or Neoadjuvant Systemic Therapy. Ann Surg Oncol 32(2):983-984, 2025. e-Pub 2025. PMID: 39562422.
- Tripathy D, Blum JL, Karuturi MS, McCune S, Kurian S, Moezi M, Anderson D, Gauthier E, Zhang Z, Montelongo MZ, Wang Y, Rocque GB. Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial. Oncologist, 2024. e-Pub 2024. PMID: 39475418.
- Muppidi N, Adesoye T, Yi M, Sun SX, Chavez-MacGregor M, Singh P, Karuturi M, Tamirisa N, Hunt KK, Teshome M. Clinical Outcomes in Patients with Early Stage Node-Negative HER2-Positive Breast Cancer Receiving Upfront Surgery or Neoadjuvant Systemic Therapy. Ann Surg Oncol, 2024. e-Pub 2024. PMID: 39192013.
- Singareeka Raghavendra, A, Liu, D, Shen, Y, Barcenas, CH, Ueno, NT, Giordano, SH, Tripathy, D, Karuturi, MS. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy. Breast Cancer Research and Treatment 207(1):81-90, 2024. e-Pub 2024. PMID: 38916821.
- Raghavendra AS, Jennings K, Guerra G, Tripathy D, Karuturi MS. Patient-reported convenience and effectiveness of telehealth for breast cancer management. Oncologist. e-Pub 2024. PMID: 39017637.
- Blum JL, DiCristo C, Gordon D, Karuturi MS, Oubre D, Jepsen E, Cuevas J, Lakhanpal S, Montelongo MZ, Zhang Z, Cappelleri JC, Wang Y, Tripathy D. Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study. Breast Cancer Res Treat 203(3):463-475, 2024. e-Pub 2024. PMID: 37903899.
- Giridhar, KV, Suman, VJ, Tang, X, Ye, H, Campbell, JD, Mayer, E, Karuturi, MS, Morikawa, A, Kimmick, G, Isaacs, C, Oh, SY, Clark, A, Park, BH, Bucheit, L, Tsai, J, Ingle, JN, Goetz, MP, D’Assoro, AB, Kalari, KR, Haddad, T. Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
- Karuturi MS, Cappelleri JC, Blum JL, Patel K, Telivala B, McCune S, Cuevas JD, Lakhanpal S, Montelongo MZ, Wang Y, Tripathy D, Rocque GB. Measures of functional status in older patients treated with palbociclib for advanced breast cancer. J Geriatr Oncol 15(1):101670, 2024. e-Pub 2024. PMID: 38061288.
- Ring A, Karuturi M, Smyth EN, Lokhandwala T, Sheffield KM, Willey J, Lunacsek O, Sapunar F, Cui ZL, Coutinho AD, Rybowski S. Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice. Drugs Real World Outcomes. e-Pub 2023. PMID: 37775689.
- Haddad TC, Suman VJ, D'Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Oh SY, Clark AS, Mayer IA, Keyomarsi K, Hobday TJ, Peethambaram PP, O'Sullivan CC, Leon-Ferre RA, Liu MC, Ingle JN, Goetz MP. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. JAMA Oncol 9(6):815-824, 2023. e-Pub 2023. PMID: 36892847.
- Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
- Ring A, Karuturi M, Smyth EN, Lokhandwala T, Sheffield KM, Willey J, Lunacsek O, Sapunar F, Cui ZL, Coutinho A, Rybowski S. Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice. Adv Ther 40(5):2515-2523, 2023. e-Pub 2023. PMID: 36995468.
- Mitin N, Nyrop KA, Strum SL, Knecht A, Carey LA, Reeder-Hayes KE, Claire Dees E, Jolly TA, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, O'Hare EA, Muss HB. A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer. NPJ Breast Cancer 8(1):103, 2022. e-Pub 2022. PMID: 36075910.
- Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, Collaborative Group TNTBP, Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer 8(2):e33859, 2022. e-Pub 2022. PMID: 35588361.
- Karuturi MS, Giordano SH, Hoover DS, Volk RJ, Housten AJ. Exploring and supporting older women's chemotherapy decision-making in early-stage breast cancer. J Geriatr Oncol 13(2):170-175, 2022. e-Pub 2022. PMID: 34955445.
- Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK. Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer. Cancer Med 11(6):1474-1483, 2022. e-Pub 2022. PMID: 35128817.
- Nyrop KA, Damone EM, Deal AM, Wheeler SB, Charlot M, Reeve BB, Basch E, Shachar SS, Carey LA, Reeder-Hayes KE, Dees EC, Jolly TA, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Wood WA, Muss HB. Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer. Breast Cancer Res Treat 191(2):409-422, 2022. e-Pub 2022. PMID: 34739658.
- Gelmon K, Walshe JM, Mahtani R, Joy AA, Karuturi M, Neven P, Lu DR, Kim S, Schnell P, Bananis E, Schwartzberg L. Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2. Breast 59:321-326, 2021. e-Pub 2021. PMID: 34388698.
- Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clin Cancer Res 27(15):4177-4185, 2021. e-Pub 2021. PMID: 33722897.
- Tamirisa N, Lin H, Shen Y, Shaitelman SF, Karuturi MS, Giordano SH, Babiera GV, Bedrosian I. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-a National Cancer Database analysis. Cancer 127(13):2196-2203, 2021. e-Pub 2021. PMID: 33735487.
- Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs 39(2):509-515, 2021. e-Pub 2021. PMID: 32984932.
- Nyrop KA, Deal AM, Chen YT, Reeve BB, Basch EM, Wood WA, Shachar SS, Carey LA, Reeder-Hayes KE, Dees EC, Jolly TA, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Lee JT, Brenizer A, Muss HB. Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer. Cancer 127(6):957-967, 2021. e-Pub 2021. PMID: 33216355.
Review Articles
- Giza, DE, Gonzalez, A, Karuturi, MS, Ghosh, S, Holmes, HM, Naik, AD. Patient Priorities Care for older breast cancer survivors. Journal of Clinical Oncology 43:TPS1662-TPS1662, 2025. e-Pub 2025.
- Samjoo IA, Hall A, Chen C, Nguyen BN, Bartlett M, Smith ML, Harbeck N, Cappelleri JC, Karuturi M, Makari D, Arruda LS, Sandin R, Hanson K, Doan J. A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib. J Comp Eff Res 13(10):e240111, 2024. e-Pub 2024. PMID: 39254990.
Abstracts
- Clifton KK, Karuturi MS. Examining progression free survival, overall survival, and toxicities of palbociclib in a geriatric population. J Clin Oncol.
Book Chapters
- Carlson, KA, Liang, DH, Fayanju, OM, Garvey, PB, Karuturi, MS, Bedrosian, I, Hunt, KK. Surgical Procedures for Advanced Local and Regional Malignancies of the Breast, 627,640.e1-640,640.e4, 2023.
Patient Reviews
CV information above last modified September 10, 2026